

Economic plan

This plan identifies the areas prioritised for economic modelling. The final analysis may differ from those described below. The rationale for any differences will be explained in the guideline.

1 Guideline

Chronic obstructive pulmonary disease in over 16s: diagnosis and management

2 List of modelling questions

Review questions by scope area	In people with stable COPD, what is the clinical and cost effectiveness of a LAMA plus a LABA compared with: <ul style="list-style-type: none"> • a LAMA alone • a LABA alone • a LABA plus an inhaled corticosteroid (ICS)
Population	Adults with stable COPD whose symptoms are not adequately controlled using short-acting bronchodilators.
Interventions and comparators considered for inclusion	<ul style="list-style-type: none"> • LABA • LAMA • LABA+ICS • LAMA+LABA
Perspective	Costs: NHS and Personal Social Services (PSS). Outcomes: All direct health effects.
Outcomes	Discounted quality adjusted life years (QALYs) Discounted costs Incremental cost-effectiveness ratios (ICER) Net monetary benefit (NMB)
Type of analysis	Cost–utility analysis using a state-transition model
Issues to note	N/A